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Introduction. Retinoblastoma is a childhood cancer of the retina originated by altered or null 
retinoblastoma protein (pRb) expression. Genetic alterations in both RB1 alleles in the retinal cells are 
required for the development of retinoblastoma. In the sporadic form, non-hereditary RB1 gene mutations 
take place in a single retinoblast cell, and are therefore only present in tumor DNA (somatic mutations). 
Sporadic retinoblastoma is primarily unilateral, lacks family history and has no risk of transmission to 
descendants. Genetic tests for detection of RB1 mutation has improved the identification of carriers 
and facilitated accurate genetic counseling. 
Objective. To identify mutations in the RB1 gene in Colombian patients with sporadic retinoblastoma 
by PCR-SSCP followed by sequence.
Materials and methods. Four patients with sporadic retinoblastoma were analyzed by PCR-SSCP, 
followed by DNA sequencing to identify variations in the RB1 gene.
Results. We identified five variations in RB1 gene: three new mutations (one germline and two somatic 
mutations), one new polymorphism and one already reported somatic mutation. Four mutations were 
found in three patients with unilateral retinoblastoma and one mutation was found in a patient with 
bilateral retinoblastoma. One of these was a germline mutation in a sporadic unilateral retinoblastoma 
that was not present in the parents or three siblings analyzed.
Conclusions. Our results emphasize the importance of identifying mutations for genetic counseling 
and clinical management of sporadic retinoblastoma patients. Description of a new RB1 gene variant is 
interesting since there have been a small number of polymorphisms reported for this gene.
Keywords: Retinoblastoma/genetics; genes, retinoblastoma; mutations; polymorphism, genetic; 
Colombia. 
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Identificación de tres nuevas mutaciones en el gen RB1 en pacientes con retinoblastoma 
esporádico en Colombia
Introducción. El retinoblastoma es un cáncer pediátrico de la retina originado por la expresión alterada 
o ausente de la proteína del retinoblastoma (pRb). Se requiere la alteración genética de ambos alelos 
RB1 en las células de la retina para el desarrollo del retinoblastoma. En la forma esporádica, las 
mutaciones no hereditarias del gen RB1 ocurren en un solo retinoblasto y están presentes sólo en el 
ADN del tumor (mutaciones somáticas). El retinoblastoma esporádico es generalmente unilateral, no 
tiene historia familiar y no tiene riesgo de transmisión a la descendencia. Las pruebas genéticas para 
la detección de mutaciones en RB1 han mejorado la identificación de portadores y han facilitado la 
precisión de la asesoría genética. 
Objetivo. Detectar mutaciones en el gen RB1 en pacientes colombianos con retinoblastoma esporádico 
mediante PCR-SSCP seguido de secuenciación.
Materiales y métodos. Se analizaron cuatro pacientes con retinoblastoma esporádico para la detección 
de variaciones en el gen RB1 mediante PCR-SSCP, seguida de secuenciación.
Resultados. Se identificaron cinco variaciones del gen RB1: tres mutaciones nuevas (una de línea 
germinal y dos somáticas), un polimorfismo nuevo y una mutación somática ya reportada. Las cuatro 
mutaciones se encontraron en tres pacientes con retinoblastoma unilateral y uno con bilateral. La 
mutación germinal se detectó en un paciente con compromiso unilateral y no se encontró en los padres 
ni en los tres hermanos analizados.
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Conclusión. Estos resultados enfatizan la importancia, para asesoría genética y manejo clínico, de 
identificar mutaciones del gen RB1 en pacientes con retinoblastoma esporádico. La descripción de 
una nueva variante en RB1 es interesante, dado el muy bajo número de polimorfismos reportados 
para este gen.
Palabras clave: retinoblastoma/genética, genes de retinoblastoma, mutación, polimorfismo genético, 
Colombia. 
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Retinoblastoma (RB) is an eye cancer of the 
developing retina in early childhood which has 
an estimated incidence of 1:20,000 live births. It 
originates in altered or null retinoblastoma protein 
(pRb) expression. pRb is a nuclear phosphoprotein 
of 928 amino acid with an MW of 110 kDa which 
has a very important role in regulation of the cell 
cycle G1/S check point (1). pRb is coded by the 
retinoblastoma gene (RB1), located on chromosome 
13q14.2, which was the first tumor suppressor gene 
identified (2-4). The RB1 gene is 183 kb in length, 
is composed of 27 exons, and encodes a 4.7 kb 
mRNA (4). Genetic alterations in both RB1 alleles 
in the retinal cells are required for the development 
of retinoblastoma (5).
This tumor has two presentations: sporadic (60%) 
and familial (40%). In the sporadic form, non-
hereditary RB1 gene mutations take place in a 
single retinoblast cell and are therefore only present 
in tumor DNA (somatic mutations). Sporadic RB 
is mainly unilateral, lacks family history, and has 
no risk of transmission. On the other hand, in the 
familial form of RB the first mutation is inherited 
as a germ-line mutation. Therefore all tissues 
are expected to carry one copy of the mutated 
RB1 gene. This first mutation can be transmitted 
to the descendants as a susceptibility risk factor. 
The second inactivating mutation is somatic and 
is present only in tumor DNA. Most patients with 
familial RB have bilateral, multifocal, or early onset 
tumors (5); however, nearly 15% of familial RB 
cases present as unilateral tumors (6-10).
The development of sensitive and reliable genetic 
tests to detect RB1 mutations has improved 
identification of carriers and facilitated accurate 
genetic counseling. To date, a total of 1165 unique 
RB1 DNA variants including polymorphisms and 
mutations have been registered in the Leiden 
Open Variation Database (LOVD). RB1 mutations 
show an extensive heterogeneity without hot 
spots. Different techniques have been used 
to identify genetic variations in the RB1 gene. 
The single strand conformation polymorphism 
(SSCP) technique has been used to screen for 
mutations before confirmatory sequencing is 
performed (11-15). This technique is based on the 
sequence-dependent migration patterns of single-
stranded DNA fragments as they migrate through 
nondenaturing polyacrylamide gel electrophoresis.
The aim of this study was to identify mutations 
in the RB1 gene in Colombian patients with 
sporadic retinoblastoma by PCR-SSCP followed by 
sequence. In this study we report the identification 
of three new RB1 gene mutations in four patients 
with sporadic retinoblastoma in Colombia. We also 
describe a new RB1 gene variant that increases 
the small number of polymorphisms reported for 
this gene.
Materials and methods
Patients
Four sporadic RB patients referred to the Instituto de 
Genética (Universidad Nacional de Colombia) by 
the Ophthalmology service of the Instituto Nacional 
de Cancerología - Bogotá, Colombia, Hospital de 
La Misericordia and Fundación Carlos Ardila Lulle 
were analyzed after proper informed consent was 
obtained and approved by Institutional Review 
Board (IRB) (Universidad Nacional de Colombia).
Three patients had unilateral tumors and one had a 
bilateral tumor at the time of diagnosis. No previous 
history of RB was present in any of the patients’ 
families.
DNA from each patient was obtained from whole 
blood and from tumors by phenol-chloroform 
extraction followed by ethanol precipitation. Some 
formaldehyde fixed and paraffin embedded (FFPE) 
tumors where extracted following the protocol 
reported by Goelz et al (16). In addition, DNA 
was obtained from whole blood from parents and 
siblings in selected cases (table 1).
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Table 1. Patients analyzed in this study
Patient RB Sex Age at diagnosis               DNA extracted from DNA from 
   (months)  Blood Tumor relatives
RB 153 Unilateral Male 36 + + Father
RB 175 Unilateral Female 30 + + Parents, siblings (3)
RB 177 Unilateral Male 8 + + Parents
RB 181 Bilateral Male 17 + Right eye tumor+ Parents
     Left eye tumor+ 
+: DNA obtained for analysis.
DNA amplification
PCR amplification of the promoter and 27 exons of 
the RB1 gene was performed using primers design 
by Hogg et al (17) including flanking intron region for 
each exon that range from 42 to 344pb depending 
on the exon. Amplification was performed in a 25 μl 
of total volume containing 100 ng of genomic DNA, 
20 nmol of each dNTP, 1 unit of Taq polymerase 
(Promega Corporation, Madison, WI, USA) and 
50 pmol of each primer (Oligo Therapeutics Inc, 
USA), in standard buffer conditions, except that for 
the promoter and exon 1 2.5% DMSO was used. 
Thermal cycling conditions consisting of thirty 
cycles of denaturing for 30 sec at 94 °C, annealing 
for 30 sec to 55 °C-62 °C and extension at 72 °C for 
1 min were performed in a PTC-100 (MJ Research, 
Waltham, USA) followed by an additional 10 min 
at 72 °C. In table 2 we describe the annealing 
temperatures and the lengths of PCR products.
Single strand conformational polymorphism 
(SSCP)
In order to optimize SSCP, the large PCR fragments 
were digested with restriction enzymes as previously 
described (17) (Table 2). Non-isotopic SSCP 
analysis was performed in 6-10% polyacrylamide 
gel containing 5% (v/v) glycerol, in 0.5X TBE buffer. 
Table 2. Conditions and restriction enzymes used to amplified the promoter and 27 exons of the RB1 gene by PCR followed by 
SSCP (17).
Exon Annealing Full Restriction enzyme Restriction
 temperature (°C) size (bp)   size (bp)
PRO 62 570 SmaI, BspHI 230/176/164
1 62 370 DdeI 153/154
2 60 409 HpaI 214/191
3 58 477 AluI 243/234
4 58 445 RsaI 269/176
5 58 488 AflIII, TaqI 218/142/128
6 58 326 AluI 179/147
7 60 491 RsaI 193/176/61
8 55 316 TaqI 192/124
9 60 316 EcoRI 171/145
10 60 492 BglII, HinfI 225/218/49
11 55 294 MboII 163/131
12 60 465 BclI, RsaI 198/162/105
13 60 570 EcoRI, HinfI 232/225/113
14 58 212 - -
15-16 55 361 NdeI 209/152
17 55 555 RsaI, NdeI, Sau3aI 142/119/104/101/89
18 58 221 BclI 113/108
19 62 485 HinfI, MluI 218/176/91
20 60 350 HpaII 177/173
21 58 518 AseI, NdeI 180/173/164
22 60 363 BclI 210/153
23 58 420 BspNI, AluI 186/136/98
24 58 579 BstEII, HindIII, BspNI 235/200/93/50
25 60 625 BspNI, Bsp1286I 266/198/161
26 60 524 PstI, NsiI 215/166/143
27 62 218 - -
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Briefly, 1 μl of amplified products (with or without 
digestion) was diluted in 3 μl of denaturing buffer 
(formamide 95%, 10 mM EDTA, 10mM NaOH, 
0.05% xylene cyanol, 0.05% bromophenol blue). 
Immediately prior to loading, diluted samples were 
denatured at 95°C for three minutes and chilled 
in ice to minimize renaturation. Samples were 
electrophoresed at 200 V for 6 hours at room 
temperature. DNA was visualized by silver-staining. 
Briefly, gels were fixed for 20 min in 10% (v/v) glacial 
acetic acid. After three washes with deionized water 
for 2 min each, gels were stained with 0.2% (w/v) 
AgNO3 solution for 20 min, washed with deionized 
water, and developed in sodium carbonate (30 g/L), 
0.4% (v/v) formaldehyde for 10 min.
Sequencing
DNA amplicons that showed bandshift variation in 
SSCP gels were cloned into the pGEM-T vector 
and used to transform JM109 competent cells 
(Promega Corporation, Madison, WI, USA) following 
manufacturers recommendations. Plasmid DNA 
isolation was carried out using Wizard Minipreps 
kits (Promega Corporation, Madison, WI, USA). 
DNA sequence was carried out using Sequenase T7 
version 2.0 kit (Amersham Corporation, Piscataway, 
NJ 08854 USA), following manufacturers 
recommendations, and electrophoresed in 6% 
polyacrylamide gel. Mutations identified were on 
the RB1 genomic sequence (GenBank accession 
number: L11910).
Results
An exon by exon SSCP analysis of the RB1 gene 
followed by sequencing was performed for the four 
sporadic RB patients. Five RB1 gene variations 
were found in these four patients (table 1, figure 
1). Three of the variations detected were somatic 
mutations and two were germinal mutations which 
were detected in both whole blood and tumors. 
When a germline mutation was identified in a 
patient, parents and siblings were also analyzed 
for the same mutation. Four of the five genetic 
variations detected were new and have not yet been 
registered in the Leiden Open Variation Database 
(LOVD) (table 3). 
RB 153: The propositus was a boy with unilateral 
RB diagnosed at three years of age (figure 2A). 
SSCP of exon 20 showed bandshift in the tumor 
DNA but not in blood DNA (somatic mutation) 
(figure 2B). Sequencing showed a g.156785C>T 
mutation causing a nonsense mutation in codon 
685(Q685X) (figure 2C). This mutation had been 
previously reported by Najera et al (18) in a patient 
with bilateral RB as a germline mutation.
RB 175: The propositus was a girl with unilateral RB 
diagnosed at two years of age (figure 3A). SSCP of 
exon 20 showed alteration in both the tumor and 
blood (figure 3B y 3C). DNA sequencing showed 
two heterozygous variations in the RB1 gene 
(figure 3D y 3E). One variation was a C deletion 
in codon 661, g.156712delC, causing a frameshift 
mutation introducing a premature stop codon at 
662 (figure 3D). This mutation was present in both 
the patient´s tumor and blood (germline mutation) 
but absent in her parents and siblings. The second 
mutation found g.IVS20+2T>G was present only in 
tumor DNA (somatic mutation). It was a transition 
in the invariant nucleotide of the splice donor site of 
intron 20 that probably destroyed this splice donor 
site (figure 3E).
RB 177: The propositus was a boy with unilateral 
RB diagnosed at eight months of age (figure 4A). 
SSCP analysis of exon 19 showed motility alteration 
in tumor DNA (figure 4B). Sequencing showed 
a g.153293T>C mutation, causing a missense 
mutation in codon 634 (S634P) (figure 4C). This 
mutation was heterozygous in the tumor and was 
not detected in blood (somatic mutation).
RB 181: The propositus was a boy with bilateral 
RB diagnosed at seventeen months of age (figure 
5A). SSCP analysis of exon 17 showed motility 
alteration both in blood and tumor DNA (figure 
5B). Sequencing showed a silent homozygous 
g.78216A>G mutation in codon 544 (E544E) 
(figure 5C). This mutation was also present as a 
homozygous change in the boy’s father.
Discussion
One of the most important challenges for clinical 
management of RB patients and their families is 
Figure 1. Distribution of the five RB1 variations identified. A. 
Structure of RB1 gene showing 27 exons (red lines) and introns 
(gray line). B. Structure of RB1 mRNA showing 27 exons (red 
boxes). 
g.78216A>G
g.IVS20+2T>G
18-23 24-273-6 7-11 12-17
g.156712delC
g.153293T>C
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B.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 16 17 18 19 20 21 22 23 25 27
g.156785C>T
1 2
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to identify genetically predisposed individuals 
by detection of germline causative mutation in 
RB patients. Screening for constitutional RB1 
mutation should become an integral part of current 
management of any patient and relatives affected 
by retinoblastoma. The presence or absence of 
a germline mutation in RB1 in a patient without 
family history is very important because distinguish 
between hereditary and non-hereditary RB and it will 
supply critical information for prognosis, treatment 
planning, follow-up care, genetic counseling, 
presymptomatic diagnosis and enable in uterus 
screening. Children with heritable RB, in addition 
to experiencing bilateral vision impairment in early 
childhood, are at increased risk for developing 
primitive neuroectodermal tumors and second 
tumors later in life. The genetically predisposed 
individuals can be screened ophthalmologically 
and the tumors treated as they arise.Unequivocal 
identification of mutant gene carriers will also 
eliminate the need for costly and time-consuming 
procedures for family members who are not carriers 
(19,20). On the other hand, the large size of the 
RB1 gene (180 kb), its high degree of mutational 
heterogeneity, the high proportion of mutations 
arise from small (< 10 bp) sequence changes and 
the presence of mosaicism and the possibility 
of mutation within non-coding regions make it 
very difficult to achieve efficient detection of RB1 
mutations for all patients. For these reasons despite 
the RB1 gene was the first tumor suppressor gene 
to be identified, many patients and their families 
have never benefited from genetic testing (21).
In the present study, non-isotopic SSCP and 
sequencing were used to analyze four sporadic 
RB patients. Five RB1 gene variants were found 
in three patients with unilateral RB and one patient 
with bilateral RB. Four out of five RB1 gene 
variations detected corresponded to mutations 
with expected changes in the pRb and the other 
is a silent mutation that not change de amino acid 
sequence in the pRb.
A B. C.. Control Control RB153B RB153T RB153 Blood RB153 Tumor
Wild type: TTC AG CAA Mutant: TTC AG CAA
Phe Gln His
C T
Phe Stop
Codon: 684 685 686 684 685 686
A
A
A
A
G
T
C
G
G
A
A
A
A
G
T
C
G
A
G A T C G A T C
Figure 2. Case RB153. A. Pedigree: The half-filled square indicates unilateral RB in the propositus. B.SSCP analysis of exon 20 
digested with HpaI. The arrows point out an extraband present only in tumor but not in blood. C. Sequencing of the complementary 
strand showed a g.156785C>T mutation (Q685X).
Table 3. DNA variations identified in RB1 gene in four RB sporadic cases from Colombia
Case RB Site Codon  Descriptiona  Expected  Recurrencesb Alleles Tissue Origen Presence 
(Sex)     Consequence     in relativesc
153 U Ex 20 685  g.156785C>T  GlnStop Yes (1) Homozygous T Somatic NT
(M)
175 U Ex 20 661 g.156712delC  Frameshift
(F)     Codon 662>Stop No Heterozygous  B, T Germline None 
  In 20 IVS+2  g.IVS20+2T>G SD destroyed No Heterozygous T Somatic NT
177 U Ex 19 634 g.153293T>C  SerPro No Heterozygous T Somatic NT
(M)
181 B Ex 17 544  g.78216A>G  Silent
(M)     Polymorphism? No Homozygous B, T Germline Father
aDescription follows the recommendations published by den Dunnen and Antonarakis (2000) using a genomic sequence (GenBank: L11910.1). 
bNumber of ocurrences (in brackets) in previously published RB1 mutations (see text). cOnly carried out when germline mutation was identified. RB: 
Retinoblastoma, M: Male, F: Female, U: Unilateral, B: Bilateral, SD: splice donor site, T: Tumor, B: Blood. NT: Not tested. 
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Mutant: ACC CCA GCC
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Figure 4. Case RB177. A. Pedigree: The half-filled square indicates unilateral RB in the propositus. B. SSCP of exon 19 digested 
with MluI: The arrows point out aextraband present only in tumor (RB177T) but not in blood (RB177B). Two different amplicons from 
exon 19 RB 177T are shown. C. Sequencing of complementary strand showed a g.153293C>T (S634P).
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Figure 3. Case RB175. A. Pedigree: The half-filled circle indicates unilateral RB in the propositus. B. SSCP analysis of exon 20 
without digestion: The arrows points out two extrabands present both in tumor and blood DNA of RB 175, but not in parents or three 
siblings analyzed. C. SSCP analysis of exon 20 digested with HpaI: The arrows point out a band absent in tumor, but present in blood 
DNA of RB 175 and controls. Sequencing of exon 20 showed two heterozygous variations in the RB1 gene (D,E) D. Sequencing 
of exon 20 showed a C deletion in codon 661 (g.156712delC) introducing a premature stop codon (L662X), in both the tumor and 
blood from the patient (germline mutation) but not of her parents and her siblings. E. Sequencing of exon 20 showing also showed 
a g.IVS20+2T>G only in tumor DNA.
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Interestingly, of the four mutations detected in our 
cases, three were novel mutations: g.156712delC 
(L662X), a frameshift mutation, g.153293T>C 
(S634P), a missense mutation, and g.IVS20+2T>G, 
a consensus splice junction sequence nucleotide 
change (table 3). This emphasizes for the high 
degree of mutational heterogeneity of this large 
gene. The additional mutation detected, was a 
g.156785C>T (Q685X) nonsense somatic mutation, 
that had been already reported by Najera et al (18). 
These mutations generate premature stop codons 
or affect the splicing site of the gene (table 1).
In two patients with unilateral RB, we detect only 
somatic mutations. The absence of germline 
mutation in these patients indicates that they 
correspond to non-hereditary RB and they don’t 
have risk to transmission for his offspring.
The detection of a germline mutation in unilateral 
RB175 emphasizes the importance of identifying 
these mutations for genetic counseling in families 
with an RB child. This case was a unilateral RB 
case without family history. However, the mutation 
detected was a germline mutation not present in 
any of the relatives. The absence of this mutation 
in parents and siblings indicates that this mutation 
may have arisen in the patient herself in the zygote 
or very early post-zygote stage, or it could represent 
a germline mosaicism inherited from one of her 
parents. Recently, Bunin et al (22) reported an 
association between gonadal radiation exposure in 
men and women and new germline RB1 mutations 
detectable in their children. However, no radiation 
exposure history could be documented in our 
case. The detection of a germline mutation in this 
patient with unilateral RB is very important for 
her management because she has an increased 
risk to develop a RB in the other eye and is 
probably that she can develop a second tumor 
in her life. Since the germline mutation was only 
detected in the patient, she will have a 50% risk for 
transmission to her offspring and with de germline 
causative mutation identified in this study could 
be possible identified genetically predisposed 
individuals in her descendants. In RB 175 we also 
identify a somatic mutation that correspond to 
second-hit because is only present in tumor.
The other variant was a g.78216A>G in codon 
544 (E544E), homozygous silent point mutation 
present in the RB181 patient and his father which is 
probably a novel polymorphism. Because it doesn’t 
change the amino acid codified by codon 544 and it 
is present in unaffected parent, and doesn’t have a 
clinical significance. Although the RB1 gene spans 
over 180 kb, only a few polymorphisms within 
this locus have been identified. Ten RB1 gene 
variants without noticeable phenotypic effects are 
registered in the Leiden Open Variation Database 
(LOVD). This new polymorphism detected in a 
Colombian family could represent a variation of the 
RB1 gene at the population level. In this patient we 
cannot identify a causative mutation in tumor not in 
blood. Probably this obeys to sensitivity of SSCP 
method or the possibility or other kind of alteration 
that is not possible to detect by methodology 
used for this study (e.g. large deletion, mutation in 
non-coding regions situated outside the explored 
sequences, hypermethylation or other epigenetic 
alteration) (23). This is a bilateral RB and for this 
reason his offspring has a 50% to develop RB but 
in this case is necessary for appropriate genetic 
counseling perform other techniques that can 
identify the germline mutation.
Wild type: ACAAG GAAA
Thr Arg Glu
Codon: 684 685 686
Mutant: ACAAG GAA
Thr Arg Glu
684 685 686
G
G A T C G A T C
B. C.Control Control RB177T RB17TB RB177B RB 181 Blood RB 181 Father
RB 181
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T
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Figure 5. Case RB181. A. Pedigree: The filled square indicates bilateral RB in the propositus. B. SSCP analysis of exon 17 digested 
with RsaI and NdeI. The arrows point out aextraband present only in both tumors (LE: Left eye tumor, RE: Right eye tumor) but not 
in blood DNA of RB 181. C. Sequencing of complementary strand showed a g.78216A>G (E544E) silent mutation in both RB 181 
and in his father
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There are other studies in Colombia (24) and other 
Latino American countries as Cuba (24), Argentina 
(25,26), Brazil (27) and Mexico (14,28) that report, 
in some cases with almost the same methodology, 
different mutations, that confirms the high degree 
of variability of mutational spectrum in RB1 gene.
Many techniques, different of PCR-SSCP, had 
been use alone or in combination to detected RB1 
mutation. These techniques includes: denaturing 
gradient gel electrophoresis (DGGE)or heteroduplex 
analysis (12,26), multiplex ligation dependent probe 
amplification (MLPA) (29) high performance liquid 
chromatography (HPLC) (6,7), Southern blot (9), 
fluorescent in situ hybridization (FISH) (9), protein 
truncation testing (PTT) (8) and PCR-RFLP (10). No 
single genetic testing method currently available can 
detect all RB1 mutation types. The most effective 
and efficient strategies to date have used a series 
of nested tests. The European Genetics Quality 
Network has a guideline for molecular analysis 
of retinoblastoma (13).These protocols, some of 
which have used as many as 5 different testing 
modalities, are costly, time consuming and the final 
sensitivities ranges up to 83% (never 100%) (30). 
These characteristics reduces clinical utility and 
is important in the future develop a more efficient 
method for routine genetic testing with clinical use.
When mutational screening failed to identify the 
disease-causing mutation the use of polymorphic 
short tandems (STR) as recommended by the 
Best Practice Guidelines of the European Molecular 
Genetics Quality Network (EMQN) for indirect testing 
of RB1 and useful for establish loss of heterozygosity 
(LOH). Recently, Munier el at report an algorithm based 
on linkage analysis that identified patients with true 
risk (31). High-throughput methodologies as whole-
genome sequencing, whole gene sequencing and 
SNP array methodologies have been used to identify 
underlying alternative mechanisms of RB genesis not 
known at present (32).
In conclusion, the present study describes three 
new RB1 gene mutations with clinical relevance for 
genetic counseling and clinical management of RB 
patients, and describes a new RB1 gene variant 
that increases the small number of polymorphisms 
detected in this gene.
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